Compare S&P500 ETF (SPY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs TG Therapeutics Inc — how do they compare? S&P500 ETF trades at $778.47 (market cap $821.54B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: S&P500 ETF is far larger — about 100.7× TG Therapeutics Inc's market cap, and S&P500 ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold S&P500 ETF for 205 Days and TG Therapeutics Inc for 16 Days on average.
| SPY | TGTX | |
|---|---|---|
Market Cap | $821.54B | $8.16B |
Volume | 40,070,358 | 1,735,121 |
52-Week High | $779.14 | $59.06 |
52-Week Low | $631.99 | $26.94 |
Typical Hold Time | 205 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY, the SPDR S&P 500 ETF, trades at $778.54, up 0.16% on the day, with a bullish technical signal driven by moving averages. The ETF is positioned near resistance at $777, with support at $771. Recent news highlights mixed sentiment, with some articles noting strong profit growth expectations for the S&P 500 in 2026 but potential headwinds from margin debt and slowing growth forecasts for 2027.
The outlook for SPY remains tied to broader market trends, with opportunities from potential year-end rallies and strong corporate earnings, but risks include macroeconomic volatility and elevated valuations. Investor sentiment is cautious amid warnings about market collapses and shifting profit growth projections.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
